Moderna shares soar over 120% on personalised cancer vaccine breakthrough

Moderna's shares surged more than 120% at the start of Wednesday's trading session after the company announced, alongside Merck, that it had developed a personalised cancer vaccine with promising clinical trial results. The breakthrough marks one of the biggest single-day gains in the biotech firm's history.